AdaptVac is at the forefront of vaccine development, utilizing innovative capsid Virus-Like Particle (cVLP) technology to create effective therapeutic and prophylactic vaccines. Their lead candidate, the ABNCoV2 COVID-19 vaccine, has shown promising results in Phase 3 trials, demonstrating non-inferiority to existing mRNA vaccines while maintaining a strong safety profile. The cVLP platform allows for the stable display of vaccine antigens, enhancing immunogenicity and durability of antibody responses. This technology is based on a proprietary split-protein conjugation system that simplifies the generation of stable antigen-cVLP complexes, making it a significant advancement over traditional methods that often require extensive optimization.

In addition to the COVID-19 vaccine, AdaptVac is involved in developing vaccines for other infectious diseases, including Nipah virus and filoviruses, through collaborative efforts in the VICI-DISEASE consortium. Their iso-peptide display platform, which incorporates the MoonCatcher/Tag system and Bacteriophage AP205 capsid protein, has been validated through clinical testing, demonstrating its safety and regulatory acceptance. This versatile platform has the potential to address a wide range of diseases, including cancer, as evidenced by their HER2+ cancer vaccine candidate, ES2B-C001, which has shown strong preclinical efficacy. Overall, AdaptVac's innovative technologies position them as a key player in the future of vaccine development.

Denmark

AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines. 

The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders. The combination of ExpreS2ion’s proprietary insect cell expression technology, ExpreS2, and NextGen’s unique expertise in proprietary Virus-Like Particle (VLP) technology makes us a strong and versatile player in the field of new vaccines and immune therapy.

AdaptVAC

Company Details